Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended 6 Months Ended
Oct. 31, 2024
Oct. 31, 2023
Oct. 31, 2024
Oct. 31, 2023
Income Statement [Abstract]        
Revenue $ 0 $ 0 $ 0 $ 0
Operating expenses:        
Research and development costs 97,470 82,033 193,486 186,516
Compensation expense 283,333 229,159 672,817 469,157
Director fees 138,000 306,738 276,000 356,953
Legal and professional 469,685 519,073 980,241 844,301
General and administrative 117,572 272,517 252,403 1,627,919
Total operating expenses 1,106,060 1,409,520 2,374,947 3,484,846
Loss from operations (1,106,060) (1,409,520) (2,374,947) (3,484,846)
Other income (expenses):        
Interest income 382,562 894,181 929,994 1,770,059
Change in fair value of warrant liability 1,829,000 4,075,000 3,913,000 2,623,000
Change in fair value of derivative liability 980,000 (769,000) 2,184,000 (1,299,000)
Change in fair value of convertible note receivable 435,000 0 680,000 0
Change in fair value of warrant asset - Femasys 276,000 0 (1,234,000) 0
Change in fair value of investment - TNF (4,265,000) 0 (3,540,734) 0
Gain on related party investment - TNF 0 0 21,395,734 0
Other expense (1,062) (765) (1,252) (2,614)
Total other income, net (363,500) 4,199,416 24,326,742 3,091,445
Net income (loss) (1,469,560) 2,789,896 21,951,795 (393,401)
Preferred stock dividends (443,958) (586,886) (1,129,759) (906,735)
Preferred stock accretion (1,045,357) (4,461,097) (3,193,404) (7,733,130)
Net income (loss) attributable to common stockholders $ (2,958,875) $ (2,258,087) $ 17,628,632 $ (9,033,266)